表紙
市場調査レポート

不眠症:世界薬剤予測および市場分析

PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 329464
出版日 ページ情報 英文 377 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
不眠症:世界薬剤予測および市場分析 PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023
出版日: 2015年02月27日 ページ情報: 英文 377 Pages
概要

不眠症は最も一般的な睡眠障害であり、世界人口のおよそ35%が患っているといわれています。不眠症市場は広くジェネリック化されており、これが新製品にとっての競合環境を作り出しています。2014年4月に、不眠症薬として売上トップのSunovion/大日本住友製薬のLunestaの独占性が失われたことから、同市場はさらに減少する見込みです。しかし新規クラスから2つのパイプライン製品が上市予定であり、市場の成長に寄与するとみられています。

当レポートでは、不眠症の概要と治療法、市場収益と予測、パイプライン分析、現在および将来の競合動向、各国別動向、参入企業のプロファイルなどをまとめています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態生理学
  • 分類
  • 症状
  • 予後

第4章 疫学

  • 疾患の背景
  • リスクファクターと併存疾患
  • 世界の動向
  • 予測方法
  • 急性不眠症の疫学的予測
  • 慢性不眠症の疫学的予測
  • 慢性一次性不眠症の疫学的予測
  • 慢性二次性不眠症の疫学的予測
  • ディスカッション

第5章 疾患管理

  • 診断と治療概要
    • 臨床評価
    • 紹介
    • 治療ガイドラインと主な処方薬
    • 臨床の現状
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本

第6章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド
  • その他の治療クラス

第7章 アンメットニーズと機会

  • 概要
  • 安全性プロファイルを向上させた新薬
  • 長期的治療に用いることのできる薬剤
  • 認知行動療法の利用可能性
  • 睡眠の質を向上させる薬剤
  • プライマリーケア医師の教育

第8章 パイプライン評価

  • 概要
  • 治験マッピング
  • 臨床開発における有望薬剤
  • 開発の早期段階にある有望薬剤
  • その他の開発中薬剤

第9章 現在および将来の参入企業

  • 概要
  • 企業戦略動向
  • 企業プロファイル
    • Sanofi
    • Sunovion/大日本住友製薬株式会社
    • Pfizer
    • 武田薬品工業株式会社
    • Merck & Co
    • Meda
    • エーザイ株式会社
    • Purdue
    • Neurim
    • Pernix Therapeutics

第10章 市場見通し

  • 世界市場
    • 予測
    • 促進因子と障壁:世界的課題
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本

第11章 付録

図表

目次
Product Code: GDHC107PIDR

Insomnia is the most common sleep disorder and is believed to affect approximately 35% of the global population. The condition can be defined as patient-reported difficultly with sleep initiation or sleep maintenance which can include frequent awakenings, difficulty returning to sleep after awakenings, or awakening too early with inability to return to sleep. Cases of insomnia can be classified on the basis of etiology into primary and secondary (or comorbid) subtypes. The insomnia market is widely genericized creating a competitive environment for new products. As such, the treatment algorithm centers on the generically available nonbenzodiazepines and low-dose sedating antidepressants, despite the launch of numerous novel agents. The value of the insomnia market is set to further decline following the loss of exclusivity for Sunovion/Dainippon Sumitomo's Lunesta, the top selling insomnia drug, in April 2014. However, GlobalData expects the launch of two pipeline products from a novel class of drugs to provide growth in the insomnia market as they may address some of the unmet need.

Highlights

Key Questions Answered

  • The insomnia market is dominated by the generic nonbenzodiazepines and low-does sedating antidepressants. Novel products have not had a significant impact on this market as they lack notable clinical advantages over the current first-line drugs. What are the unmet needs in light of this? Will there be opportunities in this market for drug developers throughout the forecast period?
  • The current late stage insomnia pipeline is sparse with only one drug having advanced to Phase III. However, GlobalData believes two orexin receptor antagonists will enter the market during the forecast period. What impact will these drugs have on the market? How will they affect the treatment algorithm for insomnia? Will these drugs fulfil any of the unmet needs for insomnia?
  • Population aging is occurring in almost all countries worldwide, particularly in the 7MM. This is expected to have a significant impact on the prevalence of insomnia. How will epidemiological changes impact the growth of the future insomnia market?

Key Findings

  • The main driver of growth in the insomnia market will be the introduction of the orexin receptor antagonists over the forecast period. The launch of this novel drug class may address some of the unmet need in the insomnia market due to the safety profile of these drugs and the availability of long-term clinical trial data.
  • The generic erosion of Lunesta within the insomnia market will lead to a decline in market size prior to the entry of pipeline products. The availability of generic eszopiclone could greatly affect the treatment algorithm and will put downward pricing pressure on the controlled-release zolpidem generics.
  • The biggest barrier for growth in the insomnia market will be fierce competition from generic products. The commercial advantages to prescribing generic drugs will make it difficult for novel products to gain traction.
  • Considerable opportunity remains for products that meet the unmet needs in the insomnia market. Drugs with improved safety, which is sustained over the long-term, would hold a competitive advantage. Similarly, drugs that improve sleep quality would be viewed favorably by physicians.

Scope

  • Overview of insomnia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized insomnia market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the insomnia therapeutics market.
  • Pipeline analysis: focus on the three late-stage pipeline insomnia drugs discussing emerging trends as well as overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global insomnia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global insomnia therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global insomnia therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global insomnia therapeutics market from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for Acute Insomnia (2013-2023)
    • 4.5.1. Total Prevalent Cases of Acute Insomnia
    • 4.5.2. Age-Specific Total Prevalent Cases of Acute Insomnia
    • 4.5.3. Sex-Specific Total Prevalent Cases of Acute Insomnia
    • 4.5.4. Age-Standardized Total Prevalence of Acute Insomnia
  • 4.6. Epidemiological Forecast for Chronic Insomnia (Not Fulfilling DSM-IV Criteria) (2013-2023)
    • 4.6.1. Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria)
    • 4.6.2. Age-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria)
    • 4.6.3. Sex-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria)
    • 4.6.4. Age-Standardized Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria)
  • 4.7. Epidemiological Forecast for Chronic Primary Insomnia (2013-2023)
    • 4.7.1. Total Prevalent Cases of Chronic Primary Insomnia
    • 4.7.2. Age-Specific Total Prevalent Cases of Chronic Primary Insomnia
    • 4.7.3. Sex-Specific Total Prevalent Cases of Chronic Primary Insomnia
    • 4.7.4. Age-Standardized Total Prevalence of Chronic Primary Insomnia
  • 4.8. Epidemiological Forecast for Chronic Secondary Insomnia (2013-2023)
    • 4.8.1. Total Prevalent Cases of Chronic Secondary Insomnia
    • 4.8.2. Age-Specific Total Prevalent Cases of Chronic Secondary Insomnia
    • 4.8.3. Sex-Specific Total Prevalent Cases of Chronic Secondary Insomnia
    • 4.8.4. Age-Standardized Total Prevalence of Chronic Secondary Insomnia
  • 4.9. Discussion
    • 4.9.1. Epidemiological Forecast Insight
    • 4.9.2. Limitations of the Analysis
    • 4.9.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Clinical Evaluation
    • 5.1.2. Referral
    • 5.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.4. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands
    • 6.2.1. Nonbenzodiazepines
    • 6.2.2. Benzodiazepines
    • 6.2.3. Melatonin Receptor Agonists
    • 6.2.4. Low-Dose Sedating Antidepressants
    • 6.2.5. Orexin Receptor Antagonists
  • 6.3. Other Therapeutic Classes

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Novel Drugs with Improved Safety Profiles
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Drugs That Can Be Used for Long-Term Treatment
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Availability of Cognitive Behavioral Therapy
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Drugs That Improve the Quality of Sleep
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Education for Primary Care Physicians
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Sponsor Type
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. E-2006
    • 8.3.2. Piromelatine
  • 8.4. Promising Drugs in Early-Stage Development
  • 8.5. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Sanofi
    • 9.3.2. Sunovion/Dainippon Sumitomo
    • 9.3.3. Pfizer
    • 9.3.4. Takeda
    • 9.3.5. Merck & Co.
    • 9.3.6. Meda
    • 9.3.7. Eisai
    • 9.3.8. Purdue
    • 9.3.9. Neurim
    • 9.3.10. Pernix Therapeutics

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Insomnia Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: ICSD-2 Classification of Sleep Disorders and Subtypes of Insomnia
  • Table 2: Comorbid Psychiatric Disorders, Medical Disorders, Medications, and Substances that Can Cause Insomnia
  • Table 3: The Three Main Classifications of Insomnia Disorders
  • Table 4: Symptoms of Insomnia
  • Table 5: Risk Factors and Comorbidities for Insomnia
  • Table 6: DSM-IV Diagnostic Criteria for Primary Insomnia
  • Table 7: Sources of Epidemiological Data Used for the Forecast for Total Prevalent Cases of Acute Insomnia in the 7MM
  • Table 8: Sources of Epidemiological Data Used for the Forecast for Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) in the 7MM
  • Table 9: Sources of Epidemiological Data Used for the Forecast for Total Prevalent Cases of Chronic Primary Insomnia in the 7MM
  • Table 10: Sources of Epidemiological Data Used for the Forecast for Total Prevalent Cases of Chronic Secondary Insomnia in the 7MM
  • Table 11: 7MM, Total Prevalent Cases of Acute Insomnia, Both Sexes, Ages ≥15 Years, N, Select Years 2013-2023
  • Table 12: 7MM, Age-Specific Total Prevalent Cases of Acute Insomnia, Both Sexes, N (Row %), 2013
  • Table 13: 7MM, Sex-Specific Total Prevalent Cases of Acute Insomnia, Ages ≥15 Years, N (Row %), 2013
  • Table 14: 7MM, Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Both Sexes, Ages ≥15 Years, N, Select Years 2013-2023
  • Table 15: 7MM, Age-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Both Sexes, N (Row %), 2013
  • Table 16: 7MM, Sex-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Ages ≥15 Years, N (Row %), 2013
  • Table 17: 7MM, Total Prevalent Cases of Chronic Primary Insomnia, Both Sexes, Ages ≥15 Years, N, Select Years 2013-2023
  • Table 18: 7MM, Age-Specific Total Prevalent Cases of Chronic Primary Insomnia, Both Sexes, N (Row %), 2013
  • Table 19: 7MM, Sex-Specific Total Prevalent Cases of Chronic Primary Insomnia, Ages ≥15 Years, N (Row %), 2013
  • Table 20: 7MM, Total Prevalent Cases of Chronic Secondary Insomnia, Both Sexes, Ages ≥15 Years, N, 2013-2023
  • Table 21: 7MM, Age-Specific Total Prevalent Cases of Chronic Secondary Insomnia, Both Sexes, N (Row %), 2013
  • Table 22: 7MM, Sex-Specific Total Prevalent Cases of Chronic Secondary Insomnia, Ages ≥15 Years, N (Row %), 2013
  • Table 23: Examples of Patient Questionnaires Used in the Diagnosis of Insomnia
  • Table 24: Treatment Guidelines for Insomnia
  • Table 25: Most Prescribed Drugs for Insomnia by Class in the Global Markets, 2013
  • Table 26: Country Profile - US
  • Table 27: Country Profile - France
  • Table 28: Country Profile - Germany
  • Table 29: Country Profile - Italy
  • Table 30: Country Profile - Spain
  • Table 31: Country Profile - UK
  • Table 32: Country Profile - Japan
  • Table 33: Leading Treatments for Insomnia, 2015
  • Table 34: Product Profile - Ambien/Ambien CR
  • Table 35: Ambien/Ambien CR SWOT Analysis, 2015
  • Table 36: Global Sales Forecast ($m) for Ambien, 2013-2023
  • Table 37: Global Sales Forecasts ($m) for Ambien CR, 2013-2023
  • Table 38: Product Profile - Intermezzo
  • Table 39: Pivotal Trials of Intermezzo in Insomnia
  • Table 40: Intermezzo SWOT Analysis, 2015
  • Table 41: Global Sales Forecast ($m) for Intermezzo, 2013-2023
  • Table 42: Product Profile - Zolpimist
  • Table 43: Zolpimist SWOT Analysis, 2015
  • Table 44: Global Sales Forecast ($m) for Zolpimist, 2013-2023
  • Table 45: Product Profile - Edluar
  • Table 46: Edluar SWOT Analysis, 2015
  • Table 47: Global Sales Forecast ($m) for Edluar, 2013-2023
  • Table 48: Product Profile - Lunesta
  • Table 49: Adverse Events at ≥2% Incidence in Lunesta Clinical Trials
  • Table 50: Lunesta SWOT Analysis, 2015
  • Table 51: Global Sales Forecast ($m) for Lunesta, 2013-2023
  • Table 52: Product Profile - Sonata
  • Table 53: Adverse Events at ≥2% Incidence in Sonata Trials
  • Table 54: Sonata SWOT Analysis, 2015
  • Table 55: Global Sales Forecast ($m) for Sonata, 2013-2023
  • Table 56: Benzodiazepine SWOT Analysis, 2015
  • Table 57: Global Sales Forecasts ($m) for the Benzodiazepines, 2013-2023
  • Table 58: Product Profile - Hetlioz
  • Table 59: Results of a Phase III clinical trial of Hetlioz in Transient Insomnia
  • Table 60: Results of a Phase III clinical trial of Hetlioz in Chronic Insomnia
  • Table 61: Adverse Events Observed in Clinical Trials of Hetlioz
  • Table 62: Hetlioz SWOT Analysis, 2015
  • Table 63: Product Profile - Rozerem
  • Table 64: Incidence (%) of Adverse Events in Rozerem's Clinical Trials
  • Table 65: Rozerem SWOT Analysis, 2015
  • Table 66: Global Sales Forecast ($m) for Rozerem, 2013-2023
  • Table 67: Product Profile - Circadin
  • Table 68: Frequency of Adverse Reactions Observed in Clinical Trials of Circadin
  • Table 69: Circadin SWOT Analysis, 2015
  • Table 70: Global Sales Forecast ($m) for Circadin, 2013-2023
  • Table 71: Product Profile - Silenor
  • Table 72: Objective Sleep Efficacy Measures of Silenor in Chronic Primary Insomnia
  • Table 73: Objective Sleep Efficacy Measures of Silenor in Elderly Chronic Primary Insomnia Patients
  • Table 74: Subjective Sleep Efficacy Measures of Silenor in Elderly Chronic Primary Insomnia Patients
  • Table 75: Incidence (%) of Adverse Events in Silenor Trials
  • Table 76: Silenor SWOT Analysis, 2015
  • Table 77: Global Sales Forecasts ($m) for Silenor, 2013-2023
  • Table 78: Low-Dose Sedating Antidepressants SWOT Analysis, 2015
  • Table 79: Global Sales Forecast ($m) for Low-Dose Sedating Antidepressants, 2013-2023
  • Table 80: Product Profile - Belsomra
  • Table 81: Pooled Sleep Efficacy Measures from Two Phase III Trials of Belsomra in Primary Insomnia
  • Table 82: Belsomra Pooled Adverse Events at ≥2% Incidence in the First 3 Months of Phase III Clinical Trials
  • Table 83: Belsomra SWOT Analysis, 2015
  • Table 84: Global Sales Forecast ($) for Belsomra, 2013-2023
  • Table 85: Summary of Minor Therapeutic Classes, 2015
  • Table 86: Unmet Needs and Opportunities in Insomnia
  • Table 87: Product Profile - E-2006
  • Table 88: Sleep Efficacy Measures from a Phase I Trial of E-2006 in Primary Insomnia Patients
  • Table 89: E-2006 SWOT Analysis, 2015
  • Table 90: Global Sales Forecast ($) for E-2006, 2013-2023
  • Table 91: Product Profile - Piromelatine
  • Table 92: Piromelatine SWOT Analysis, 2015
  • Table 93: Drugs in Development, 2015
  • Table 94: Key Companies in the Insomnia Market in the 7MM, 2013
  • Table 95: Sanofi's Insomnia Portfolio Assessment, 2015
  • Table 96: Sunovion/Dainippon Sumitomo's Insomnia Portfolio Assessment, 2015
  • Table 97: Pfizer's Insomnia Portfolio Assessment, 2015
  • Table 98: Takeda's Insomnia Portfolio Assessment, 2015
  • Table 99: Merck's Insomnia Portfolio Assessment, 2015
  • Table 100: Meda's Insomnia Portfolio Assessment, 2015
  • Table 101: Eisai's Insomnia Portfolio Assessment, 2015
  • Table 102: Purdue's Insomnia Portfolio Assessment, 2015
  • Table 103: Neurim's Insomnia Portfolio Assessment, 2015
  • Table 104: Pernix Therapeutics' Insomnia Portfolio Assessment, 2015
  • Table 105: Global Sales Forecast ($m) for Insomnia, 2013-2023
  • Table 106: Insomnia Market - Drivers and Barriers, 2013-2023
  • Table 107: Sales Forecast ($m) for Insomnia in the United States, 2013-2023
  • Table 108: Key Events Impacting Sales for Insomnia in the US, 2013-2023
  • Table 109: Insomnia Market in the US - Drivers and Barriers, 2013-2023
  • Table 110: Sales Forecasts ($m) for Insomnia in France, 2013-2023
  • Table 111: Key Events Impacting Sales for Insomnia in France, 2013-2023
  • Table 112: Insomnia Market in France - Drivers and Barriers, 2013-2023
  • Table 113: Sales Forecast ($m) for Insomnia in Germany, 2013-2023
  • Table 114: Key Events Impacting Sales for Insomnia in Germany, 2013-2023
  • Table 115: Insomnia Market in Germany - Drivers and Barriers, 2013-2023
  • Table 116: Sales Forecast ($m) for Insomnia in Italy, 2013-2023
  • Table 117: Key Events Impacting Sales for Insomnia in Italy, 2013-2023
  • Table 118: Insomnia Market in Italy - Drivers and Barriers, 2013-2023
  • Table 119: Sales Forecast ($m) for Insomnia in Spain, 2013-2023
  • Table 120: Key Events Impacting Sales for Insomnia in Spain, 2013-2023
  • Table 121: Insomnia Market in Spain - Drivers and Barriers, 2013-2023
  • Table 122: Sales Forecast ($m) for Insomnia in the UK, 2013-2023
  • Table 123: Key Events Impacting Sales for Insomnia in the UK, 2013-2023
  • Table 124: Insomnia Market in the UK - Drivers and Barriers, 2013-2023
  • Table 125: Sales Forecast ($m) for Insomnia in Japan, 2013-2023
  • Table 126: Key Events Impacting Sales for Insomnia in Japan, 2013-2023
  • Table 127: Insomnia Market in Japan - Drivers and Barriers, 2013-2023
  • Table 128: Key Launch Dates
  • Table 129: Key Patent Expiries
  • Table 130: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: The "3P" Model of Insomnia
  • Figure 2: Global Average of the Total Prevalence of Insomnia Symptoms and Diagnoses
  • Figure 3: Patient Flow for the Epidemiological Forecast of Insomnia in the 7MM
  • Figure 4: 7MM, Total Prevalent Cases of Acute Insomnia, Both Sexes, Ages ≥15 Years, N, 2013-2023
  • Figure 5: 7MM, Age-Specific Total Prevalent Cases of Acute Insomnia, Both Sexes, N, 2013
  • Figure 6: 7MM, Sex-Specific Total Prevalent Cases of Acute Insomnia, Ages ≥15 Years, N, 2013
  • Figure 7: 7MM, Age-Standardized Total Prevalence of Acute Insomnia (%), Ages ≥15 Years, by Sex, 2013
  • Figure 8: 7MM, Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Both Sexes, Ages ≥15 Years, N, 2013-2023
  • Figure 9: 7MM, Age-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Both Sexes, Ages ≥15 Years, N, 2013
  • Figure 10: 7MM, Sex-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria), Ages ≥15 Years, N, 2013
  • Figure 11: 7MM, Age-Standardized Total Prevalence of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) (%), Ages ≥15 Years, by Sex, 2013
  • Figure 12: 7MM, Total Prevalent Cases of Chronic Primary Insomnia, Both Sexes, Ages ≥15 Years, N, 2013-2023
  • Figure 13: 7MM, Age-Specific Total Prevalent Cases of Chronic Primary Insomnia, Both Sexes, N, 2013
  • Figure 14: 7MM, Sex-Specific Total Prevalent Cases of Chronic Primary Insomnia, Ages ≥15 Years, N, 2013
  • Figure 15: 7MM, Age-Standardized Total Prevalence of Chronic Primary Insomnia (%), Ages ≥15 Years, by Sex, 2013
  • Figure 16: 7MM, Total Prevalent Cases of Chronic Secondary Insomnia, Both Sexes, Ages ≥15 Years, N, 2013-2023
  • Figure 17: 7MM, Age-Specific Total Prevalent Cases of Chronic Secondary Insomnia, Both Sexes, N, 2013
  • Figure 18: 7MM, Sex-Specific Total Prevalent Cases of Chronic Secondary Insomnia, Ages ≥15 Years, N, 2013
  • Figure 19: 7MM, Age-Standardized Total Prevalence of Chronic Secondary Insomnia (%), Ages ≥15 Years, by Sex, 2013
  • Figure 20: Insomnia Diagnosis Algorithm
  • Figure 21: Chronic Insomnia Treatment Algorithm
  • Figure 22: Belsomra's Development in Insomnia
  • Figure 23: Insomnia Therapeutics - Sponsor Type, 2015
  • Figure 24: Insomnia - Phase II-III Pipeline, 2015
  • Figure 25: Clinical and Commercial Positioning of E-2006
  • Figure 26: Clinical and Commercial Positioning of Piromelatine
  • Figure 27: Global Sales of Products for Insomnia by Company, 2013-2023
  • Figure 28: Company Portfolio Gap Analysis in Insomnia, 2013-2023
  • Figure 29: Sanofi SWOT Analysis in Insomnia, 2013-2023
  • Figure 30: Sunovion/Dainippon Sumitomo SWOT Analysis in Insomnia, 2013-2023
  • Figure 31: Pfizer SWOT Analysis in Insomnia, 2013-2023
  • Figure 32: Takeda SWOT Analysis in Insomnia, 2013-2023
  • Figure 33: Merck SWOT Analysis in Insomnia, 2013-2023
  • Figure 34: Meda SWOT Analysis in Insomnia, 2013-2023
  • Figure 35: Eisai SWOT Analysis in Insomnia, 2013-2023
  • Figure 36: Purdue SWOT Analysis in Insomnia, 2013-2023
  • Figure 37: Neurim SWOT Analysis in Insomnia, 2013-2023
  • Figure 38: Pernix Therapeutics SWOT Analysis in Insomnia, 2013-2023
  • Figure 39: Global Sales for Insomnia by Region, 2013-2023
  • Figure 40: Sales for Insomnia in the United States by Drug Class, 2013-2023
  • Figure 41: Sales for Insomnia in France by Drug Class, 2013-2023
  • Figure 42: Sales for Insomnia in Germany by Drug Class, 2013-2023
  • Figure 43: Sales for Insomnia in Italy by Drug Class, 2013-2023
  • Figure 44: Sales for Insomnia in Spain by Drug Class, 2013-2023
  • Figure 45: Sales for Insomnia in the UK by Drug Class, 2013-2023
  • Figure 46: Sales for Insomnia in Japan by Drug Class, 2013-2023
Back to Top